These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16842888)

  • 41. Cellular reactivity to the p. Falciparum protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation.
    Flanagan KL; Plebanski M; Odhiambo K; Sheu E; Mwangi T; Gelder C; Hart K; Kortok M; Lowe B; Robson KJ; Marsh K; Hill AV
    Am J Trop Med Hyg; 2006 Mar; 74(3):367-75. PubMed ID: 16525093
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children.
    Genton B; Al-Yaman F; Betuela I; Anders RF; Saul A; Baea K; Mellombo M; Taraika J; Brown GV; Pye D; Irving DO; Felger I; Beck HP; Smith TA; Alpers MP
    Vaccine; 2003 Dec; 22(1):30-41. PubMed ID: 14604568
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers.
    Vuola JM; Keating S; Webster DP; Berthoud T; Dunachie S; Gilbert SC; Hill AV
    J Immunol; 2005 Jan; 174(1):449-55. PubMed ID: 15611270
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique.
    Macete E; Aponte JJ; Guinovart C; Sacarlal J; Ofori-Anyinam O; Mandomando I; Espasa M; Bevilacqua C; Leach A; Dubois MC; Heppner DG; Tello L; Milman J; Cohen J; Dubovsky F; Tornieporth N; Thompson R; Alonso PL
    Trop Med Int Health; 2007 Jan; 12(1):37-46. PubMed ID: 17207146
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant.
    Ophorst OJ; Radosević K; Klap JM; Sijtsma J; Gillissen G; Mintardjo R; van Ooij MJ; Holterman L; Companjen A; Goudsmit J; Havenga MJ
    Vaccine; 2007 Aug; 25(35):6501-10. PubMed ID: 17646036
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.
    Kimani D; Jagne YJ; Cox M; Kimani E; Bliss CM; Gitau E; Ogwang C; Afolabi MO; Bowyer G; Collins KA; Edwards N; Hodgson SH; Duncan CJ; Spencer AJ; Knight MG; Drammeh A; Anagnostou NA; Berrie E; Moyle S; Gilbert SC; Soipei P; Okebe J; Colloca S; Cortese R; Viebig NK; Roberts R; Lawrie AM; Nicosia A; Imoukhuede EB; Bejon P; Chilengi R; Bojang K; Flanagan KL; Hill AV; Urban BC; Ewer KJ
    Mol Ther; 2014 Nov; 22(11):1992-2003. PubMed ID: 24930599
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques.
    Stewart VA; Walsh DS; McGrath SM; Kester KE; Cummings JF; Voss G; Delchambre M; Garçon N; Cohen JD; Heppner DG
    Vaccine; 2006 Oct; 24(42-43):6493-502. PubMed ID: 16911849
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Prime/Boost PfCS14K
    Vijayan A; Mejías-Pérez E; Espinosa DA; Raman SC; Sorzano COS; Zavala F; Esteban M
    Clin Vaccine Immunol; 2017 May; 24(5):. PubMed ID: 28298290
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.
    Gordon DM; McGovern TW; Krzych U; Cohen JC; Schneider I; LaChance R; Heppner DG; Yuan G; Hollingdale M; Slaoui M
    J Infect Dis; 1995 Jun; 171(6):1576-85. PubMed ID: 7769295
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.
    de Barra E; Hodgson SH; Ewer KJ; Bliss CM; Hennigan K; Collins A; Berrie E; Lawrie AM; Gilbert SC; Nicosia A; McConkey SJ; Hill AV
    PLoS One; 2014; 9(12):e115161. PubMed ID: 25522180
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Kester KE; Cummings JF; Ockenhouse CF; Nielsen R; Hall BT; Gordon DM; Schwenk RJ; Krzych U; Holland CA; Richmond G; Dowler MG; Williams J; Wirtz RA; Tornieporth N; Vigneron L; Delchambre M; Demoitie MA; Ballou WR; Cohen J; Heppner DG;
    Vaccine; 2008 Apr; 26(18):2191-202. PubMed ID: 18387719
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants.
    Afolabi MO; Tiono AB; Adetifa UJ; Yaro JB; Drammeh A; Nébié I; Bliss C; Hodgson SH; Anagnostou NA; Sanou GS; Jagne YJ; Ouedraogo O; Tamara C; Ouedraogo N; Ouedraogo M; Njie-Jobe J; Diarra A; Duncan CJ; Cortese R; Nicosia A; Roberts R; Viebig NK; Leroy O; Lawrie AM; Flanagan KL; Kampman B; Bejon P; Imoukhuede EB; Ewer KJ; Hill AV; Bojang K; Sirima SB
    Mol Ther; 2016 Aug; 24(8):1470-7. PubMed ID: 27109630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expression and immunogenicity of the Plasmodium falciparum circumsporozoite protein: the role of GPI signal sequence.
    Ophorst OJ; Radosević K; Ouwehand K; van Beem W; Mintardjo R; Sijtsma J; Kaspers J; Companjen A; Holterman L; Goudsmit J; Havenga MJ
    Vaccine; 2007 Feb; 25(8):1426-36. PubMed ID: 17161889
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A new boost for malaria vaccines.
    Pouniotis DS; Proudfoot O; Minigo G; Hanley JC; Plebanski M
    Trends Parasitol; 2004 Apr; 20(4):157-60. PubMed ID: 15099550
    [No Abstract]   [Full Text] [Related]  

  • 55. Protection against Plasmodium falciparum challenge induced in Aotus monkeys by liver-stage antigen-3-derived long synthetic peptides.
    Perlaza BL; Valencia AZ; Zapata C; Castellanos A; Sauzet JP; Blanc C; Cohen J; Arévalo-Herrera M; Corradin G; Herrera S; Druilhe P
    Eur J Immunol; 2008 Sep; 38(9):2610-5. PubMed ID: 18792413
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Do antibody responses to malaria vaccine candidates influenced by the level of malaria transmission protect from malaria?
    Nebie I; Tiono AB; Diallo DA; Samandoulougou S; Diarra A; Konate AT; Cuzin-Ouattara N; Theisen M; Corradin G; Cousens S; Ouattara AS; Ilboudo-Sanogo E; Sirima BS
    Trop Med Int Health; 2008 Feb; 13(2):229-37. PubMed ID: 18304269
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers.
    Brown AE; Singharaj P; Webster HK; Pipithkul J; Gordon DM; Boslego JW; Krinchai K; Su-archawaratana P; Wongsrichanalai C; Ballou WR
    Vaccine; 1994 Feb; 12(2):102-8. PubMed ID: 8147091
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparing human T cell and NK cell responses in viral-based malaria vaccine trials.
    Berthoud TK; Fletcher H; Porter D; Thompson F; Hill AV; Todryk SM
    Vaccine; 2009 Dec; 28(1):21-7. PubMed ID: 19837090
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants.
    Leach A; Drakeley CJ; D'Alessandro U; Fegan GW; Bennett S; Ballou WR; Targett GA; Greenwood BM
    Parasite Immunol; 1995 Aug; 17(8):441-4. PubMed ID: 7501425
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults.
    Kester KE; McKinney DA; Tornieporth N; Ockenhouse CF; Heppner DG; Hall T; Wellde BT; White K; Sun P; Schwenk R; Krzych U; Delchambre M; Voss G; Dubois MC; Gasser RA; Dowler MG; O'Brien M; Wittes J; Wirtz R; Cohen J; Ballou WR;
    Vaccine; 2007 Jul; 25(29):5359-66. PubMed ID: 17574311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.